Management of MLL-rearranged ALL

Share :
Published: 18 Oct 2018
Views: 1827
Prof Rob Pieters - Princess Maxima Centre for paediatric oncology (UU), Utrecht, Netherlands

Prof Rob Pieters talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the management of MLL-rearranged ALL.

Prof Pieters discusses what these rearrangements mean for prognosis and also for screening and the treatment selection.

He goes on to talk about the new targets in therapy: demethylating agents and HDAC inhibitors.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.